In both the training and validation data sets, the platinum-chemotherapy-free interval alone performed poorly in discriminating a patient's prognosis (C-indices 0.559 and 0.558, respectively).
Interestingly, in our study no correlation was observed between plasma DNA concentrations and the three biochemical markers already used to assess prognosis (C-reactive protein, brain natriuretic peptide and procalcitonin).
In addition to pathological analysis of blind bone marrow biopsy, MRI and PET can help to (a) estimate initial BMI and assess the stage of disease, (b) indicate prognosis and (c) assess response to treatment.
Identification of the underlying genetic cause of FADS/MPS facilitates clinical management by providing (a) precise genetic diagnosis, (b) enabling accurate predictions of recurrence risk and prognosis and (c) allowing the possibility of prenatal diagnosis.
In addition to bone marrow biopsy, MRI can help to (a) estimate initial BMI and assess the stage of disease, (b) indicate prognosis and (c) assess response to treatment.
Accordingly, type A and B tumours did not show lymphatic metastasis and had better prognosis; type C had an occasional lymphatic metastasis and a relatively poor prognosis; types D, E and F with the least GGO were progressive with the worst clinical outcome.
Based on Beleut et al. [34], CSS was significantly worse for patients in the poor prognosis clusters C (HR: 2.21; p = 0.034) and B (HR: 2.46; p = 0.002) than for those in cluster A, although CSS of clusters B and C showed no significant difference.
We re-evaluated the prognosis of C-KIT, IGF1R in comparison with that of MMSET.
In poor prognosis patients, C-BOP/BEP should be compared to standard chemotherapy of four cycles of BEP.
However, our analysis also reveals that AKAP12 under-expression is likely not involved in the poor-prognosis subtype C tumors, a finding that may have an important clinical implication.
